Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Item request has been placed! ×
Item request cannot be made. ×
  Processing Request
  • Additional Information
    • Affiliation:
      a Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
      b University of Edinburgh, Edinburgh, UK
      c Institut Universitaire de Cardiologie et Pneumologie, Université Laval, Québec City, QC, Canada
      d ECLA, Estudios Clínicos Latinoamérica, Rosario, Argentina
      e Eli Lilly and Company, Indianapolis, IN, USA
      f St John's Research Institute, Bangalore, India
      g Department of Medicine, University of Washington, Seattle, WA, USA
      h Department of Medicine, Oregon Health & Science University Portland, OR, USA
      i Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden
      j Instituto Dante Pazzanese de Cardiologia and University Santo Amaro, São Paulo, Brazil
      k Medical University of South Carolina, Charleston, SC, USA
      l Yonsei University Health System, Seoul, South Korea
      m Endocrinology and Nutrition Department, Hospital Clínic i Universitari, Barcelona, Spain
      n Memphis Veterans Affairs Medical Center, Memphis, TN, USA
      o Mossakowski Medical Research Centre, Polish Academy of Sciences and Central Clinical Hospital MSWiA, Warsaw, Poland
      p Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
      q Department of Internal Medicine, Dresden Technical University, Dresden, Germany
      r Victoria University of Wellington, Wellington, New Zealand
      s University Hospital Motol, Prague, Czech Republic
      t Semmelweis University, Hungarian Institute of Cardiology, Budapest, Hungary
      u Universidad de La Frontera, Temuco, Chile
      v Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, ON, Canada
      w Research Institute, FOSCAL and Medical School, Universidad de Santander UDES, Bucaramanga, Colombia
      x Universidad de Guadalajara Centro Universitario de Ciencias de la Salud, Guadalajara, Mexico
      y Latvijas Universitate, Riga, Latvia
      z National Medical Research Center of Cardiology, Moscow, Russia
      aa University of Cape Town, Cape Town, South Africa
      ab Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
      ac Taichung Veterans General Hospital, Taichung, Taiwan
      ad Robert Koch Medical Centre, Sofia, Bulgaria
    • Subject Terms:
    • Abstract:
      Summary Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A1c (HbA1c) concentrations. We assessed the effect of the GLP-1 receptor agonist dulaglutide on major adverse cardiovascular events when added to the existing antihyperglycaemic regimens of individuals with type 2 diabetes with and without previous cardiovascular disease and a wide range of glycaemic control.
    • Abstract:
      Findings Between Aug 18, 2011, and Aug 14, 2013, 9901 participants (mean age 66·2 years [SD 6·5], median HbA1c 7·2% [IQR 6·6–8·1], 4589 [46·3%] women) were enrolled and randomly assigned to receive dulaglutide (n=4949) or placebo (n=4952). During a median follow-up of 5·4 years (IQR 5·1–5·9), the primary composite outcome occurred in 594 (12·0%) participants at an incidence rate of 2·4 per 100 person-years in the dulaglutide group and in 663 (13·4%) participants at an incidence rate of 2·7 per 100 person-years in the placebo group (hazard ratio [HR] 0·88, 95% CI 0·79–0·99; p=0·026). All-cause mortality did not differ between groups (536 [10·8%] in the dulaglutide group vs 592 [12·0%] in the placebo group; HR 0·90, 95% CI 0·80–1·01; p=0·067). 2347 (47·4%) participants assigned to dulaglutide reported a gastrointestinal adverse event during follow-up compared with 1687 (34·1%) participants assigned to placebo (p<0·0001).
    • Abstract:
      Interpretation Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors.
    • Abstract:
      Funding Eli Lilly and Company.
    • ISSN:
      0140-6736
    • Accession Number:
      10.1016/S0140-6736(19)31149-3
    • Accession Number:
      S0140673619311493
    • Copyright:
      © 2019 Elsevier Ltd. All rights reserved.
  • Citations
    • ABNT:
      ABELLA, M. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet, [s. l.], v. 394, n. 10193, p. 121–130, 2019. Disponível em: . Acesso em: 24 ago. 2019.
    • AMA:
      Abella M, Alebuena A, Almagro S, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019;394(10193):121-130. doi:10.1016/S0140-6736(19)31149-3.
    • APA:
      Abella, M., Alebuena, A., Almagro, S., Amoroso, E., Anadon, P., Andreu, E., … Temelkova-Kurktschiev, T. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet, 394(10193), 121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
    • Chicago/Turabian: Author-Date:
      Abella, Mercedes, Andrea Alebuena, Sandra Almagro, Eduardo Amoroso, Paula Anadon, Elizabeth Andreu, Guillermo Aristimuño, et al. 2019. “Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial.” The Lancet 394 (10193): 121–30. doi:10.1016/S0140-6736(19)31149-3.
    • Harvard:
      Abella, M. et al. (2019) ‘Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial’, The Lancet, 394(10193), pp. 121–130. doi: 10.1016/S0140-6736(19)31149-3.
    • Harvard: Australian:
      Abella, M, Alebuena, A, Almagro, S, Amoroso, E, Anadon, P, Andreu, E, Aristimuño, G, Arzadun, M, Barbieri, M, Barcudi, R, Bartolacci, I, Bolobanich, G, Bordonava, A, Bustamante Labarta, M, Bustos, B, Caccavo, A, Camino, A, Cantero, M, Carignano, M, Cartasegna, L, Cipullo, M, Commendatore, V, Conosciuto, V, Costamagna, O, Crespo, C, Cuello, J, Cuneo, C, Cusimano, S, Dean, S, Dituro, C, Dominguez, A, Farah, M, Fernandez, A, Fernandez, F, Ferrari, A, Flammia, P, Fuentealba, J, Gallardo, KB, Garcia, C, Garcia Duran, R, Garrido, M, Gavicola, R, Gerbaudo, C, Gilli, G, Giotto, AP, Godoy Bolzán, P, Gomez Vilamajo, O, Guerlloy, F, Guridi, C, Gutierrez Garrido, N, Hasbani, E, Hermida, S, Hominal, M, Hrabar, A, Ingaramo, A, Izzicupo, A, Krynski, M, Lagrutta, M, Lanchiotti, P, Langhe, M, Leonard, V, Llanos, J, Lopez Santi, R, Lowenstein, J, Luquez, C, Mackinnon, I, Mana, M, Manzur, S, Marino, J, Martella, C, Martinez, R, Matias, R, Matkovich, J, Meritano, M, Montaña, O, Mulazzi, M, Ochoa, J, Paterlini, G, Pelagagge, M, Peralta Lopez, ME, Prado, A, Pruyas, L, Racca, M, Ricotti, C, Rodriguez, C, Romero Vidomlansky, M, Ronderos, R, Sadowski, AL, Sala, J, Sánchez, A, Santoro, A, Schiavi, L, Sein, M, Sernia, V, Serra, L, Sicer, M, Smith, T, Soso, L, Sposetti, G, et al. 2019, ‘Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial’, The Lancet, vol. 394, no. 10193, pp. 121–130, viewed 24 August 2019, .
    • MLA:
      Abella, Mercedes, et al. “Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial.” The Lancet, vol. 394, no. 10193, July 2019, pp. 121–130. EBSCOhost, doi:10.1016/S0140-6736(19)31149-3.
    • Chicago/Turabian: Humanities:
      Abella, Mercedes, Andrea Alebuena, Sandra Almagro, Eduardo Amoroso, Paula Anadon, Elizabeth Andreu, Guillermo Aristimuño, et al. “Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial.” The Lancet 394, no. 10193 (July 13, 2019): 121–30. doi:10.1016/S0140-6736(19)31149-3.
    • Vancouver/ICMJE:
      Abella M, Alebuena A, Almagro S, Amoroso E, Anadon P, Andreu E, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet [Internet]. 2019 Jul 13 [cited 2019 Aug 24];394(10193):121–30. Available from: http://ezproxy.parker.edu/login?url={targeturl}